share_log

Novavax | DEF 14A: Definitive information statements

Novavax | DEF 14A: Definitive information statements

諾瓦瓦克斯醫藥 | DEF 14A：股東委託書決議
美股sec公告 ·  04/29 07:57
Moomoo AI 已提取核心訊息
Novavax, Inc. (NVAX), a biotechnology company specializing in the discovery, development, and commercialization of innovative vaccines, announced the amendment and restatement of its 2015 Stock Incentive Plan and 2013 Employee Stock Purchase Plan. The amendments, subject to stockholder approval, propose an increase in the number of shares available for issuance under both plans. The 2015 Stock Incentive Plan seeks an additional 6,500,000 shares, while the Employee Stock Purchase Plan requests an increase of 1,000,000 shares. These changes aim to attract, retain, and motivate employees by aligning their interests with those of stockholders through equity ownership. The announcement was made in preparation for Novavax's 2024 Annual Meeting of Stockholders, scheduled for June 13, 2024, where stockholders will vote on these and other proposals, including the election of directors and the ratification of Ernst & Young LLP as the company's independent auditor for the fiscal year ending December 31, 2024.
Novavax, Inc. (NVAX), a biotechnology company specializing in the discovery, development, and commercialization of innovative vaccines, announced the amendment and restatement of its 2015 Stock Incentive Plan and 2013 Employee Stock Purchase Plan. The amendments, subject to stockholder approval, propose an increase in the number of shares available for issuance under both plans. The 2015 Stock Incentive Plan seeks an additional 6,500,000 shares, while the Employee Stock Purchase Plan requests an increase of 1,000,000 shares. These changes aim to attract, retain, and motivate employees by aligning their interests with those of stockholders through equity ownership. The announcement was made in preparation for Novavax's 2024 Annual Meeting of Stockholders, scheduled for June 13, 2024, where stockholders will vote on these and other proposals, including the election of directors and the ratification of Ernst & Young LLP as the company's independent auditor for the fiscal year ending December 31, 2024.
專門從事創新疫苗發現、開發和商業化的生物技術公司Novavax, Inc.（NVAX）宣佈修訂和重述其2015年股票激勵計劃和2013年員工股票購買計劃。修正案須經股東批准，提議增加這兩個計劃下可供發行的股票數量。2015年的股票激勵計劃要求增加650萬股，而員工股票購買計劃則要求增加1,000,000股。這些變化旨在通過股權所有權使員工的利益與股東的利益保持一致，從而吸引、留住和激勵員工。該公告是爲定於2024年6月13日舉行的Novavax2024年年度股東大會做準備的，屆時股東將對這些提案和其他提案進行投票，包括選舉董事和批准安永會計師事務所作爲截至2024年12月31日的財年的公司獨立核數師。
專門從事創新疫苗發現、開發和商業化的生物技術公司Novavax, Inc.（NVAX）宣佈修訂和重述其2015年股票激勵計劃和2013年員工股票購買計劃。修正案須經股東批准，提議增加這兩個計劃下可供發行的股票數量。2015年的股票激勵計劃要求增加650萬股，而員工股票購買計劃則要求增加1,000,000股。這些變化旨在通過股權所有權使員工的利益與股東的利益保持一致，從而吸引、留住和激勵員工。該公告是爲定於2024年6月13日舉行的Novavax2024年年度股東大會做準備的，屆時股東將對這些提案和其他提案進行投票，包括選舉董事和批准安永會計師事務所作爲截至2024年12月31日的財年的公司獨立核數師。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息